{"id":"W2297570742","doi":"10.1200/jco.2009.27.15_suppl.e15019","title":"A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Capecitabine; Bevacizumab; Clinical endpoint; Irinotecan; Internal medicine; Colorectal cancer; Oncology; FOLFIRI; Phases of clinical research; Progression-free survival; Gastroenterology; Toxicity; Cancer; Chemotherapy; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002447165,0.001547875,0.002634548,0.0005610764,0.0004958428,0.0009748371,0.001014061,0.001314802,0.003316171],"category_scores_gemma":[0.001267042,0.001035945,0.001218638,0.000634715,0.001363005,0.001077036,0.0004981808,0.003219199,0.0008205978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032369,"about_ca_system_score_gemma":0.002323019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001046132,"about_ca_topic_score_gemma":0.002924779,"domain_scores_codex":[0.9992343,0.0003975361,0.00005007616,0.0001383548,0.00006157547,0.0001181786],"domain_scores_gemma":[0.9988258,0.0002030824,0.000184523,0.00008109344,0.00005773767,0.000647608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7468473,0.1603246,0.007627553,0.0005814203,0.0009305103,0.0003433505,0.0003796909,0.001992662,0.03474316,0.0001666592,0.001697914,0.04436506],"study_design_scores_gemma":[0.4818677,0.5057883,0.008629986,0.00001449004,0.0002497626,0.0001768928,0.00003914396,0.000687522,0.001299969,0.00006857863,0.001158454,0.0000192239],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945309,0.0007692506,0.0003776406,0.0001998053,0.00008042019,0.002843105,0.0003723291,0.00003725203,0.0007893878],"genre_scores_gemma":[0.9887903,0.001089399,0.002179156,0.0006961809,0.0002146415,0.00379835,0.001306545,0.00002362262,0.001901798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003316171,"threshold_uncertainty_score":0.01294196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06320891869052882,"score_gpt":0.44045099126666,"score_spread":0.3772420725761312,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}